Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	May 31, 2023	Dec. 31, 2022	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of stock options exercised	$ 3.4	$ 9.8
Weighted average grant date fair value of share-based awards granted	$ 85.7	$ 76.64
Weighted average grant date fair value of restricted stock units granted	$ 174.86
Total unrecognized compensation cost	$ 66.0
Unrecognized compensation cost, weighted average remaining requisite service period	2 years 10 months 17 days
Number of unvested options and restricted stock units	2,156,681
Common stock, shares issued	55,774,706			55,557,698
Avitide
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued			42,621
Earnout consideration earned			50.00%
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance					2,778,000
Incentive options, vesting period	1,704,118
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period	5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested	$ 32.3	$ 40.4
Weighted average grant date fair value of restricted stock units granted	$ 174.86	$ 191.55
Restricted Stock Unit
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock	$ 159.01